J&J goes blockbuster hunting (again) with $245M cash upfront for next-gen CAR-T
J&J is working on creating its next Legend. Only this time, it’s moving right into the driver’s seat instead of taking the co-pilot role.
This morning the pharma giant put out word that it’s forking over $245 million in a hefty cash upfront to land global development and commercialization rights to two early-stage, autologous CAR-T therapy programs from a US/China player — CBMG — that has a track record of allying itself with the biggest names in the development world. And they’re going right after B-cell malignancies.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.